AbobotulinumtoxinA for the treatment of overactive bladder

References

• Abrams P, Artibani W, Cardozo L, et al. On behalf of the international continence society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol. Uro- dyn. 2009;28:287.
   PubMedGoogle Scholar
• Abrams P, Cardozo L, Khoury S., et al. Incontinence. 5th. S.l.: European Association of Urology; 2013.
   Google Scholar
• Rantell A. The role of botulinum toxin A in the management of neurogenic lower urinary tract symptoms. British Journal of Neuroscience Nursing. 2015;10(6):299–303.
   Google Scholar
• Chiaffarino F, Parazzini F, Lavezzari M, et al. On behalf of Gruppo Interdisciplinare di Studio Incontinenze Urinaria (GISIU). Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol. 2003;43:535–538.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health- related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108(9):1459–1471.
   PubMed Web of Science ®Google Scholar
• Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–532.
   PubMed Web of Science ®Google Scholar
• Araklitis G, Thiagamoorthy G, Hunter J, et al. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogyn J. 2017;28(8):1249–1256.
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012;4(6):315–324.
   PubMedGoogle Scholar
• Abrams P, Cardozo L, Wagg A, Wein A. (Eds) Incontinence 6th Edition (2017). Ici-ics. International Continence Society, Bristol UK, ISBN: 978-0956960733.
   Google Scholar
• Hatheway CL, Clostridium botulinum and other organisms that produce botulinum neurotoxin. Hauschild AHW, Dodds KL, eds. Vol. 2, New York: Ecology and Control in Foods; 1993. p. 3–20.
   Google Scholar
• Gasper S. The unique molecular structure of botulinum toxin A. Jpn J Med Sci Biol. 1975;28:66–69.
   PubMedGoogle Scholar
• Frevert J, Dressler D. Complexing proteins in botulinum toxin type a drugs: a help or a hindrance?  Biologics. 2010;4:325–332. doi:10.2147/BTT
   Google Scholar
• Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Data- Base Syst Rev. 2011;7:12.
   Google Scholar
• Moore KM, Hirst G, Emery S, et al. A double blind, placebo controlled, randomised, cross over study of trigone specific injections of botulinum toxin B for treating patients with idio- pathic detrusor overactivity refractory to other con- servative treatments. Neurourol Urodyn. 2009;28(7):833–834.
   Web of Science ®Google Scholar
• Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5:274–279.
   PubMed Web of Science ®Google Scholar
• Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol. 2010;57:884–890.
   PubMed Web of Science ®Google Scholar
• Harper M, Fowler CJ, Dasgupta P. Botulinum toxin and its applica- tions in the lower urinary tract. BJU Int. 2004;93:702–706.
   PubMed Web of Science ®Google Scholar
• Mangera A, Andersson K, Apostolidis A, et al. Contemporary managemtnf of lower urinary tract disease, with Botulinumtoxin A: a systematic review of botox (OnabotulinumtoxinA) and dysport (AbobotulinumtoxinA). Eur Urol. 2011;60:784–795.
   PubMed Web of Science ®Google Scholar
• EMC. Dysport 500U. EMC. [Online] 2018 Jan 03. [Cited 2018 Jan 03]. Available from: https://www.medicines.org.uk/emc/product/7261.
   Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An international urogynecolog- Ical Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.
   PubMed Web of Science ®Google Scholar
• Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44:165–174.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Mohammadi B, Dengler R, et al. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either botox or dysport. J Neural Transm. 2010;117:759–763.
   PubMed Web of Science ®Google Scholar
• Karsai S, Adrian R, Hammes S, et al. A randomized double-blind study of the effect of botox and dysport/reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol. 2007;143:1447–1449.
   PubMed Web of Science ®Google Scholar
• Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. A. Dv Neurol. 1998;78:231–235.
   PubMedGoogle Scholar
• Karsenty G, Baverstock R, Carlson K, et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Sl Int J Clin Pract. 2014;68(6):731–742.
   PubMedGoogle Scholar
• Chapple C, Sievert KD, Macdiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and uri- nary incontinence: a randomised, double-blind pla- cebo-controlled trial. Eur Urol. 2013;64(2):249–256.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–2193.
   PubMed Web of Science ®Google Scholar
• Manecksha RP, Cullen IM, Ahmad S, et al. Prospective randomized controlled trial compering trigonal versus trigone-sparing intra- detrusor injection of botulinum toxin A for refractory idiopathic detrusor overactivity. Eur Urol Suppl. 2011;10:191.
   Web of Science ®Google Scholar
• Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivi- ty: urodynamic outcome and patient satisfaction. Neurourol Urodyn. 2007;26:531–536.
   PubMed Web of Science ®Google Scholar
• Jeffery S, Fynes M, Lee F, et al. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007;100:1302–1306.
   PubMed Web of Science ®Google Scholar
• Pickett A. Toxicon. 2009;54:683–689.
   PubMed Web of Science ®Google Scholar
• Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13(Suppl 4):10–19.
   PubMed Web of Science ®Google Scholar
• Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin—from laboratory to bedside. Neurotox Res. 2006;9:133–140.
   PubMed Web of Science ®Google Scholar
• Carli L, Montecucco C, Rossetto O. assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–380.
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD-S, Aoki KR, Dolly JO, et al. Intramuscular injection of 125I-botulinum neurotoxin complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003;42:461–469.
   PubMed Web of Science ®Google Scholar
• Trinda de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007 Jan;33:S37–4.
   PubMed Web of Science ®Google Scholar
• Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov. 2012;2: tre-02-85-417-1.
   PubMedGoogle Scholar
• Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin. A Arch Dermatol. 2004;140:1351–1354.
   PubMedGoogle Scholar
• Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a doubleblind, randomized, dose-ranging study. J Neurol. 2008;255:1932–1939.
   PubMed Web of Science ®Google Scholar
• Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41:335–340.
   PubMed Web of Science ®Google Scholar
• Grise P, Ruffion A, Denys P, et al. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur Urol. 2010;58:759–766.
   PubMed Web of Science ®Google Scholar
• Mohee A, Khan A, Harris N, et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111:106–113.
   PubMed Web of Science ®Google Scholar
• Denys P, Del Popolo G, Amarenco G, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport (AbobotulinumtoxinA) in patients suffering from refractory Neurogenic Detrusor Overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36:457–462.
   PubMed Web of Science ®Google Scholar
• Grosse J, Kramer G, Jakse G. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int. 2009;104:651–656.
   PubMed Web of Science ®Google Scholar
• Mangera A, Apostolidis A, Andersson K, et al. An updated systematic review and statisticl comparison of standardised mean outcomes for the use of botulinum toxin in the mnagment of lower urinary tract disorders. Eur Urol. 2014;65:981–990.
   PubMed Web of Science ®Google Scholar
• Ravindra P, Jackson B, Parkinson R. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference? BJU Int. 2013;112:94–99.
   PubMed Web of Science ®Google Scholar
• Irwin P, Somov P, Ekwueme K. Patient reported outcomes of abobotulinumtoxinA injection treatment for idiopathic detrusor overactivity: a pragmatic approach to management in secondary care. J Clin Urol. 2013;6:59–63.
   Google Scholar
• Peyronnet B, Roumiguié M, Castel-Lacanal E, et al. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity. Neurourol Urodyn. 2016;35:267–270.
   PubMed Web of Science ®Google Scholar
• Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R&D. 2015;15:1–9.
   PubMed Web of Science ®Google Scholar
• Schurch B, De Seze M, Denys P, et al. otulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6- month study. J Urol. 2005;174:196–200.
   PubMed Web of Science ®Google Scholar
• Kessler TM, Khan S, Panicker J, et al. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009;113:1046–1051.
   PubMed Web of Science ®Google Scholar
• Compe ́ Rat E, Reitz A, Delcourt A, et al. Histologic features in the urinary bladder wall affected from neuro- genic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006;50:1058–1064.
   PubMed Web of Science ®Google Scholar
• Behr-Roussel E, Oger S, Pignol B, et al. Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity. Euro Urol. 2012;61:1054–1061.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British national formulary. 65 ed. London: BMJ Group and Pharmaceutical Press;2013
   Google Scholar